Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto
Ann Oncol. 2024 Nov 8:S0923-7534(24)04060-2.
doi: 10.1016/j.annonc.2024.10.011.
Online ahead of print.
1 Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: [email protected].
2 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
3 City of Hope National Medical Center, Duarte, USA.
4 Janssen Research & Development, Spring House, USA.
5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.